Analysts Set Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) PT at $14.25

Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) have earned an average rating of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $14.25.

A number of equities analysts have commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orchestra BioMed in a research note on Thursday, April 2nd. Wall Street Zen raised Orchestra BioMed from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 14th. Barclays lifted their price target on Orchestra BioMed from $11.00 to $12.00 and gave the stock an “overweight” rating in a research note on Friday, January 9th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $20.00 price target on shares of Orchestra BioMed in a research note on Thursday, March 12th.

Insider Buying and Selling

In related news, insider David P. Hochman purchased 10,000 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were acquired at an average cost of $4.29 per share, with a total value of $42,900.00. Following the purchase, the insider directly owned 1,086,467 shares of the company’s stock, valued at approximately $4,660,943.43. This trade represents a 0.93% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 8.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Orchestra BioMed

Large investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. purchased a new position in shares of Orchestra BioMed during the fourth quarter valued at approximately $38,000. Creative Planning purchased a new position in shares of Orchestra BioMed during the second quarter valued at approximately $40,000. XTX Topco Ltd purchased a new position in shares of Orchestra BioMed during the second quarter valued at approximately $45,000. Jane Street Group LLC purchased a new position in shares of Orchestra BioMed during the second quarter valued at approximately $50,000. Finally, Virtu Financial LLC purchased a new position in shares of Orchestra BioMed during the fourth quarter valued at approximately $57,000. 53.20% of the stock is owned by hedge funds and other institutional investors.

Orchestra BioMed Stock Performance

Shares of NASDAQ OBIO opened at $4.58 on Monday. The stock has a market cap of $268.02 million, a price-to-earnings ratio of -4.05 and a beta of 0.60. The company has a current ratio of 6.45, a quick ratio of 6.43 and a debt-to-equity ratio of 0.27. Orchestra BioMed has a 1-year low of $2.20 and a 1-year high of $5.42. The stock’s 50-day moving average is $4.31 and its 200 day moving average is $4.18.

Orchestra BioMed (NASDAQ:OBIO) last announced its quarterly earnings data on Thursday, March 12th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.64. The company had revenue of $30.92 million for the quarter, compared to analysts’ expectations of $0.93 million. Orchestra BioMed had a negative return on equity of 184.17% and a negative net margin of 157.40%. On average, sell-side analysts anticipate that Orchestra BioMed will post -1.66 EPS for the current fiscal year.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical?stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high?unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early? and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.